These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27045755)

  • 1. Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.
    Saber A; van der Wekken AJ; Kok K; Terpstra MM; Bosman LJ; Mastik MF; Timens W; Schuuring E; Hiltermann TJ; Groen HJ; van den Berg A
    PLoS One; 2016; 11(4):e0153065. PubMed ID: 27045755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
    Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
    Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
    J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
    Huang D; Kim DW; Kotsakis A; Deng S; Lira P; Ho SN; Lee NV; Vizcarra P; Cao JQ; Christensen JG; Kim TM; Sun JM; Ahn JS; Ahn MJ; Park K; Mao M
    Genomics; 2013 Sep; 102(3):157-62. PubMed ID: 23434628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
    J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib.
    Saraceni C; Li PM; Gainor JF; Stopyra GA; Friedman EL
    J Thorac Oncol; 2015 Jul; 10(7):1116-7. PubMed ID: 26134230
    [No Abstract]   [Full Text] [Related]  

  • 9. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
    Choi YL; Soda M; Yamashita Y; Ueno T; Takashima J; Nakajima T; Yatabe Y; Takeuchi K; Hamada T; Haruta H; Ishikawa Y; Kimura H; Mitsudomi T; Tanio Y; Mano H;
    N Engl J Med; 2010 Oct; 363(18):1734-9. PubMed ID: 20979473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.
    Campos-Gomez S; Lara-Guerra H; Routbort MJ; Lu X; Simon GR
    Int J Biol Markers; 2015 May; 30(2):e254-7. PubMed ID: 25588859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
    Ignatius Ou SH; Azada M; Hsiang DJ; Herman JM; Kain TS; Siwak-Tapp C; Casey C; He J; Ali SM; Klempner SJ; Miller VA
    J Thorac Oncol; 2014 Apr; 9(4):549-53. PubMed ID: 24736079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surviving respiratory insufficiency with intensive care support in a pretreated, extensively metastasized patient with an EML4-ALK translocation.
    van Geffen WH; Hiltermann TJ; Groen HJ
    J Thorac Oncol; 2013 Jan; 8(1):e1-2. PubMed ID: 23242444
    [No Abstract]   [Full Text] [Related]  

  • 14. BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.
    Shan L; Jiang P; Xu F; Zhang W; Guo L; Wu J; Zeng Y; Jiao Y; Ying J
    J Thorac Oncol; 2015 Jun; 10(6):e37-9. PubMed ID: 26001147
    [No Abstract]   [Full Text] [Related]  

  • 15. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.
    Okamoto I; Nakagawa K
    Cancer Sci; 2012 Aug; 103(8):1391-6. PubMed ID: 22568572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK gene aberrations and the JUN/JUNB/PDGFR axis in metastatic NSCLC.
    Berghoff AS; Birner P; Streubel B; Kenner L; Preusser M
    APMIS; 2014 Sep; 122(9):867-72. PubMed ID: 24750504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
    Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
    Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
    Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
    J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.
    Nilsson RJ; Karachaliou N; Berenguer J; Gimenez-Capitan A; Schellen P; Teixido C; Tannous J; Kuiper JL; Drees E; Grabowska M; van Keulen M; Heideman DA; Thunnissen E; Dingemans AM; Viteri S; Tannous BA; Drozdowskyj A; Rosell R; Smit EF; Wurdinger T
    Oncotarget; 2016 Jan; 7(1):1066-75. PubMed ID: 26544515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
    Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L
    Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.